Sanofi Q3 2026 non-IFRS business EPS rises 22% to €3.55

SNY•2026-10-30

Sanofi’s Q3 2026 non-IFRS business EPS rose 22% to €3.55, while net sales climbed 16% to €14.44 billion. The company upgraded its FY26 guidance.

1. Quarterly results

Sanofi reported Q3 2026 non-IFRS business EPS of €3.55, up 22%, and net sales of €14.44 billion, up 16%. It upgraded its FY26 guidance, citing strong commercial and financial momentum. The company also said an expanded Regeneron alliance opens further immunology opportunities and a Cheplapharm partnership covers legacy medicines.

Sanofi Q3 2026 non-IFRS business EPS rises 22% to €3.55

1. Quarterly results

Related News

Amrize AG: Berenberg cuts target price to $48 from $64

Saia raises target price to $468 from $463

Samsung Securities plans KRW 45 billion equity-linked bond offering

JPMorgan raises XPO target price to $207 from $205

BP posts net income of $8.46 billion, beating expectations